Day: February 8, 2022

Worksport LtdNew conception of clean energy, transportation, and life is coming soon.Mississauga, Feb. 08, 2022 (GLOBE NEWSWIRE) — Worksport Ltd (Nasdaq: WKSP) (the “Company”) management has decided to delay the unveiling of brand new energy solutions from its subsidiary Terravis Energy a few weeks to ensure all technical details are accurate and appropriately organized. Additionally, innovations that have transpired these past few weeks need to be featured in their best light, requiring more preparation time. The Terravis Energy website will provide up-to-date, accurate information on all offerings. It will answer those questions about the capabilities of its versatile, fast charging Non-Parasitic Electric Vehicle (NPEV™) systems and the Terravis Microgrid™, as well as feature several variations of these technologies...

PRESS RELEASE: 8 February 2022, 07:00 CET Biocartis and Ophiomics to Collaborate on Liver Cancer TestPrimary liver cancer1 is the sixth most common and third most lethal cancer in the world Collaboration to focus on commercialization of HepatoPredict™, a prognostic gene expression signature test to identify which patients will benefit from liver transplantationMechelen, Belgium, 8 February 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), and Ophiomics, a Lisbon (Portugal) based biotech company developing a precision medicine portfolio focused on liver cancer, today announce that they entered into a collaboration which will initially focus on the commercialization of HepatoPredict™, a prognostic gene expression signature test to help identify which...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 8, 2022 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2021. Business highlightsQUVIVIQ™ (daridorexant) 25 mg and 50 mg approved by the US Food and Drug Administration (FDA) for the treatment of adults with insomnia Marketing Authorization Application for daridorexant for the treatment of adults with insomnia under review with European Medicines Agency, Swissmedic, and Health Canada PIVLAZ™ (clazosentan) 150 mg approved in Japan for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage Commercial organizations established in key markets in Europe and scaled-up in US and Japan in preparation for first product launches Phase 3 study with selatogrel...

In Q4 2021, AS LHV Group earned EUR 19.3 million in consolidated net profit. AS LHV Pank earned EUR 18.6 million in net profit, of which EUR 3.7 million was from servicing clients related to the United Kingdom branch. AS LHV Varahaldus earned EUR 3.0 million in net profit. AS LHV Kindlustus earned EUR 0.2 million in net loss. LHV UK Limited earned EUR 1.4 million in net loss. The Group’s return on equity in Q4 was 25.7%. In terms of results, Q4 was a record quarter for LHV, with revenue also impacted by a one-off pension fund performance fee. Compared to the previous quarter, the Group’s profit increased by EUR 2.8 million (+17%) and compared to Q4 of the previous year, by EUR 1.3 million (+7%). The Group’s consolidated revenue in Q4 was EUR 42.7 million, i.e. EUR 6.6 million more than in Q3 (+18%) and EUR 7.2 million more than a year...